BCMA is considered a validated target in multiple myeloma but whether mature B-cell lymphomas can be targeted by the BCMAxCD3 T-cell redirector teclistamab is currently unknown. Here, TNFRSF17 is linked to B-cell non-Hodgkin lymphoma.